Dear Editor,

We have recently studied the manuscript titled, “Endodontic Periapical Lesion: An Overview on the Aetiology, Diagnosis and Current Treatment Modalities” by Karamifar et al. with great interest, and found the above-mentioned paper scientific and well-organised. We would also like to congratulate the authors on writing such a methodical article, which has been published by the prestigious “European Endodontic Journal” in 2020.

In the millennium of modern dentistry, specifically endodontics, aetiological factors and the consequent classification of pulp and periapical pathosis have acknowledged amendments and hence, related definitions have been altered (1, 2). Despite the long-standing concept of pulp tissue necrosis as the main contributing factor for periapical lesions, there has been a growing body of evidence that inflamed vital dental pulps are capable of causing apical periodontitis (AP) (3, 4). Studies have shown that AP can be associated with irreversible pulpitis (IP); a condition defined as an immunological response of dental pulp tissue (5, 6) to the inflammation caused mainly by microorganisms and/or their by-products (7, 8), which could result in local changes in pulp/periapical connective tissues (9, 10).

In the last decade, three-dimensional imaging, i.e. cone-beam computed tomography, has been used for accurate clinical diagnosis and revealing the presence of preoperative AP in teeth with IP; which has shown the radiographic signs of AP in 13.7% of teeth with symptomatic IP (11). Therefore, detection of AP in radiographic images does not necessarily indicate pulp necrosis; in other words, AP could be associated with pulp inflammation, and pulp necrosis may not be the sole causative factor for AP (12).

Several case reports have shown that vital pulp therapy (VPT) modalities, including direct/indirect pulp cappings as well as miniature/partial/full pulpotomies, could efficiently manage permanent teeth with clinical diagnosis of IP accompanied by AP (13-16). VPT has been also used to effectively treat permanent mature molars with hyperplastic IP associated with preoperative AP (4, 12). In two randomised clinical trials conducted by our research team, minimally invasive VPT procedures were performed to successfully treat mature permanent molars with IP accompanied by preoperative AP (17, 18). A recent randomised clinical study has investigated the effect of occlusal reduction on the postoperative pain in permanent molars with symptomatic IP associated with symptomatic AP (19). Moreover, a systematic review has reported a comprehensive investigation on symptomatic IP with/without symptomatic AP; which could/could not be diagnosed radiographically (20).

Considering the aforementioned evidence, we would like to emphasise that inflamed vital dental pulp as well as necrotic/infected pulpal tissues can cause AP, as a necrotic tooth will not necessarily cause AP, e.g. following dental trauma (11, 21). It should be noted that clinicians perform an endodontic treatment in line with their clinical findings; which could differ from bleeding to necrosis. However, when bleeding occurs, pulpitis is the most possible state of the involved tooth (22), and even with AP in radiography, minimally invasive treatment modalities, e.g. VPTs employing biomaterials, can be considered as the chosen treatment. Nevertheless, the selection of biomaterials needs to be discussed separately in future studies.

The published review by Karamifar et al. has not addressed this important aspect of pulp inflammation i.e. pulpitis, next to pulp necrosis, as an aetiological factor for AP. Vital pulp therapies, as valuable treatment modalities of inflamed vital dental pulps, are minimally invasive and could result in...
less aggression and better maintenance of tooth structure and function in the oral cavity (23). In addition, in COVID-19 pandemic outbreak, VPTs can be helpful in terms of reducing treatment time/post-endodontic pain, and consequently, lowering the risk of patient/clinician/staff exposure to the virus (24, 25).

**Disclosures**

**Conflict of interest:** The authors declare that there is no conflict of interest regarding the publication of this paper.

**Peer-review:** Externally peer-reviewed.

**Financial Disclosure:** Not applicable.

**Authorship contributions:** Concept – S.A.; Design – S.A.; Supervision – S.A., A.P.; Funding - None; Materials - None; Data collection &/or processing – S.A., A.P.; Analysis and/or interpretation – S.A., A.P.; Literature search – S.A., A.P.; Writing – S.A., A.P.; Critical Review – S.A., A.P.

**REFERENCES**

1. Glickman GN. AAE Consensus conference on diagnostic terminology: background and perspectives. J Endod 2009; 35(12):1619–20.
2. American Association of Endodontists. Endodontics: Colleagues for excellence - endodontic diagnosis. 2013. Available at: https://www.aae.org/specialty/wp-content/uploads/sites/2/2017/07/endodonticdiagnosisfall2013.pdf. Accessed Jan 22, 2021.
3. Nair PN. Pathogenesis of apical periodontitis and the causes of endodontic failures. Crit Rev Oral Biol Med 2004; 15(6):348–81.
4. Asgary S, Kemal Çalışkan M. Vital pulp therapy of a mature molar with concurrent hyperplastic pulpitis, internal root resorption and periapical periodontitis: a case report. Iran Endod J 2015; 10(4):284–6.
5. Gomes BPFA, Herrera DR. Etiologic role of root canal infection in apical periodontitis and its relationship with clinical symptomatology. Braz Oral Res 2018; 32(suppl 1):e69.
6. Asgary S, Eghbal MJ, Fazlyab M, Baghban AA, Ghoddusi J. Five-year results of vital pulp therapy in permanent molars with irreversible pulpitis: a non-inferiority multicenter randomized clinical trial. Clin Oral Investig 2015; 19(2):335–41.
7. Zheng J, Wu Z, Niu K, Xie Y, Hu X, Fu J, et al. Microbiome of deep dental caries from reversible pulpitis to irreversible pulpitis. J Endod 2019; 45(3):302–9.e1.
8. Zargar N, Ashraf H, Marashi SMA, Sabeti M, Aziz A. Identification of microorganisms in irreversible pulpitis and primary endodontic infections with respect to clinical and radiographic findings. Clin Oral Investig 2020; 24(6):2099–108.
9. Bowles WR, Withrow JC, Lepinski AM, Hargreaves KM. Tissue levels of immunoreactive substance P are increased in patients with irreversible pulpitis. J Endod 2003; 29(4):265–7.
10. Jain N, Gupta A, N M. An insight into neurophysiology of pulpal pain: facts and hypotheses. Korean J Pain 2013; 26(4):347–55.
11. Abella F, Patel S, Duran-Sindreu F, Mercadé M, Bueno R, Roig M. Evaluating the periapical status of teeth with irreversible pulpitis by using cone-beam computed tomography scanning and periapical radiographs. J Endod 2012; 38(12):1588–91.
12. Abbott PV, Yu C. A clinical classification of the status of the pulp and the root canal system. Aust Dent J 2007; 52(1 Suppl):S17–31.
13. Torabzadeh H, Asgary S. Indirect pulp therapy in a symptomatic mature molar using calcium enriched mixture cement. J Conserv Dent 2013; 16(1):83–6.
14. Asgary S, Nosrat A, Homayounfar N. Periapical healing after direct pulp capping with calcium-enriched mixture cement: a case report. Oper Dent 2012; 37(6):571–5.
15. Asgary S. Calcium-enriched mixture pulpotomy of a human permanent molar with irreversible pulpitis and condensing apical periodontitis. J Conserv Dent 2011; 14(1):90–3.
16. Asgary S, Fazlyab M, Sabbagh S, Eghbal MJ. Outcomes of different vital pulp therapy techniques on symptomatic permanent teeth: a case series. Iran Endod J 2014; 9(4):295–300.
17. Asgary S, Hassanizadeh R, Torabzadeh H, Eghbal MJ. Treatment outcomes of 4 vital pulp therapies in mature molars. J Endod 2018; 44(4):529–35.
18. Asgary S, Eghbal MJ, Ghoddusi J. Two-year results of vital pulp therapy in permanent molars with irreversible pulpitis: an ongoing multicenter randomized clinical trial. Clin Oral Investig 2014; 18(2):635–41.
19. Emara RS, Abou El Nasr HM, El Boghdadi RM. Evaluation of postoperative pain intensity following occlusal reduction in teeth associated with symptomatic irreversible pulpitis and symptomatic apical periodontitis: a randomized clinical study. Int Endod J 2019; 52(3):288–96.
20. Tampi MP, Pilcher L, Urquhart O, Kennedy E, O’Brien KK, Lockhart PB, et al. Antibiotics for the urgent management of symptomatic irreversible pulpitis, symptomatic apical periodontitis, and localized acute apical abscess: Systematic review and meta-analysis-a report of the American Dental Association. J Am Dent Assoc 2019; 150(12):e179–216.
21. Peng C, Zhao Y, Wang W, Yang Y, Qin M, Ge L. Histologic findings of a human immature revascularized/regenerated tooth with symptomatic irreversible pulpitis. J Endod 2017; 43(6):905–9.
22. Lin LM, Ricucci D, Saoud TM, Sigurdsson A, Kahler B. Vital pulp therapy of mature permanent teeth with irreversible pulpitis from the perspective of pulp biology. Aust Endod J 2020; 46(1):154–66.
23. Hanna SN, Perez Alfayate R, Prichard J. Vital pulp therapy an insight over the available literature and future expectations. Eur Endod J 2020; 5(1):46–53.
24. Asgary S, Shamszadeh S. Editorial: COVID-19 and endodontic emergencies. Iran Endod J 2020; 15(2):64.
25. Shamszadeh S, Parhizkar A, Mardani M, Asgary S. Dental considerations after the outbreak of 2019 novel coronavirus disease: a review of literature. Arch Clin Infect Dis 2020; 15(2):e103257.